Hikma Pharmaceuticals Plc (HIK) Scheduled to Post Earnings on Thursday
Hikma Pharmaceuticals Plc (LON:HIK) is scheduled to be releasing its earnings data before the market opens on Thursday, August 17th.
Hikma Pharmaceuticals Plc (LON:HIK) opened at 1308.00 on Thursday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,294.50 and a 1-year high of GBX 2,354.00. The company has a 50-day moving average price of GBX 1,435.42 and a 200-day moving average price of GBX 1,784.66. The firm’s market capitalization is GBX 3.15 billion.
A number of research analysts have recently commented on HIK shares. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 1,800 ($23.44) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 5th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 2,350 ($30.60) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, May 11th. J P Morgan Chase & Co cut their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,400 ($31.25) to GBX 1,800 ($23.44) and set a “neutral” rating for the company in a research report on Friday, May 12th. Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc to an “underperform” rating and cut their price objective for the company from GBX 2,162 ($28.15) to GBX 1,450 ($18.88) in a research report on Wednesday, May 17th. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 1,550 ($20.18) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. Hikma Pharmaceuticals Plc currently has a consensus rating of “Hold” and a consensus price target of GBX 1,936.10 ($25.21).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.